Mahavir Advanced Remedies Ltd vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of Mahavir Advanced Remedies Ltd (111489) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads 111489 vs TORNTPHARM on 8 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability13
  • Growth· not comparable
  • Size & financial health13

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

0.00
P/E ratio
78.03
0.00
P/B ratio
18.67
0.00%
Dividend yield
0.76%
₹0.12
EPS
₹63.92

Profitability

TORNTPHARM takes 3/4

How efficiently each company turns capital and sales into profit. Higher is better.

1.61%
Return on equity
27.40%
1.61%
Return on capital
15.00%
-80.00%
EBITDA margin
33.00%
140.00%
Net margin
15.29%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

Revenue CAGR (3Y) even
13.27%
Profit CAGR (3Y) even
19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹0 Cr
Market cap
₹1.88L Cr
₹0 Cr
Revenue
₹13,980 Cr
₹0 Cr
Net profit
₹2,138 Cr
0.00
Debt / equity
1.69
Mahavir Advanced Remedies Ltd
  • + ["Company is almost debt free."]
  • ["Stock is trading at 19.2 times its book value", "Company has a low return on equity of -2.33% over last 3 years.", "Working capital days have increased from 17,954 days to 30,258 days"]
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
Mahavir Advanced Remedies Ltd full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

111489 vs TORNTPHARM: Share Price, Valuation & Which to Buy | DocStoX